Porphyria Diagnostics—Part 1: A Brief Overview of the Porphyrias

Vaithamanithi‐Mudumbai Sadagopa Ramanujam1, Karl Elmo Anderson1

1 The University of Texas Medical Branch, Galveston, Texas
Publication Name:  Current Protocols in Human Genetics
Unit Number:  Unit 17.20
DOI:  10.1002/0471142905.hg1720s86
Online Posting Date:  July, 2015
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library


Porphyria diseases are a group of metabolic disorders caused by abnormal functioning of heme biosynthesis enzymes and characterized by excessive accumulation and excretion of porphyrins and their precursors. Precisely which of these chemicals builds up depends on the type of porphyria. Porphyria is not a single disease but a group of nine disorders: acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), variegate porphyria (VP), δ‐aminolevulinic acid dehydratase deficiency porphyria (ADP), porphyria cutanea tarda (PCT), hepatoerythropoietic porphyria (HEP), congenital erythropoietic porphyria (CEP), erythropoietic protoporphyria (EPP), and X‐linked protoporphyria (XLP). Each porphyria results from overproduction of heme precursors secondary to partial deficiency or, in XLP, increased activity of one of the enzymes of heme biosynthesis. Taken together, all forms of porphyria afflict fewer than 200,000 people in the United States. Based on European studies, the most common porphyria, PCT, has a prevalence of 1 in 10,000, the most common acute porphyria, AlP, has a prevalence of ∼1 in 20,000, and the most common erythropoietic porphyria, EPP, is estimated at 1 in 50,000 to 75,000. CEP is extremely rare, with prevalence estimates of 1 in 1,000,000 or less. Only six cases of ADP are documented. The current porphyria literature is very exhaustive and a brief overview of porphyria diseases is essential in order for the reader to better appreciate the relevance of this area of research prior to undertaking biochemical diagnostics procedures. This unit summarizes the current knowledge on the classification, clinical features, etiology, pathogenesis, and genetics of porphyria diseases. © 2015 by John Wiley & Sons, Inc.

Keywords: Porphyria; overview; clinical features; etiology; pathogenesis

PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • Classification, Inheritance, and Prevalence of Porphyrias
  • Acute Hepatic Porphyrias
  • Non‐Acute Hepatic Porphyrias
  • Erythropoietic Porphyrias
  • Acknowledgements
  • Literature Cited
  • Figures
  • Tables
PDF or HTML at Wiley Online Library


PDF or HTML at Wiley Online Library



Literature Cited

Literature Cited
  Aarsand, A.K., Boman, H., and Sandberg, S. 2009. Familial and sporadic porphyria cutanea tarda: Characterization and diagnostic strategies. Clin. Chem. 55:795‐803.
  Akagi, R., Kato, N., Inoue, R., Anderson, K.E., Jaffe, E.K, and Sassa, S. 2006. δ‐Aminolevulinate dehydratase (ALAD) porphyria: The first case in North America with two novel ALAD mutations. Mol. Genet. Metab. 87:329‐336.
  Albers, J.W., Robertson, W.C. Jr., and Daube, J.R. 1978. Electrodiagnostic findings in acute porphyric neuropathy. Muscle Nerve 1:292‐296.
  Anderson, K.E. 2003. Approaches to treatment and prevention of human porphyrias. In The Porphyrin Handbook, Vol. 14: Medical Aspects of Porphyrins (K.K. Kadish, K.M. Smith, and R. Guilard, eds.) pp. 247‐283. Academic Press, San Diego, Calif.
  Anderson, K.E. 2014. Chapter 152. Clinical and laboratory diagnosis of the porphyrias. In Handbook of Porphyrin Science with Applications in Chemistry, Physics, Materials Science, Engineering, Biology, and Medicine, Vol. 29: Porphyrias and Sideroblastic Anemias (G.C. Ferreira, K.M. Kadish, K.M. Smith, and R. Guilard, eds.) pp. 370‐406. World Scientific Publishing, Hackensack, N.J.
  Anderson, K.E., Drummond, G.S., Freddara, U., Sardana, M.K., and Sassa, S. 1981. Porphyrogenic effects and induction of heme oxygenase in vivo by δ‐aminolevulinic acid. Biochim. Biophys. Acta 676:289‐299.
  Anderson, K.E., Sassa, S., Bishop, D.F., and Desnick, R.J. 2001. Disorders of heme biosynthesis: X‐linked sideroblastic anemias and the porphyrias. In The Metabolic and Molecular Basis of Inherited Disease, 8th ed., Vol. II (C.R. Scriver, A.L. Beaudet, W.S. Sly, et al., eds.) pp. 2991‐3062. McGraw‐Hill, New York.
  Anderson, K.E., Bloomer, J.R., Bonkovsky, H.L., Kushner, J.P., Pierach, C.A., Pimstone, N.R., and Desnick, R.J. 2005. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann. Intern. Med. 142:439‐450.
  Anderson, K.E., Sassa, S., Bishop, D.F., and Desnick, R.J. 2011. The Online Metabolic & Molecular Basis of Inherited Disease (D.F. Bishop, ed.) pp. 1‐153. McGraw‐Hill, New York.
  Armstrong, D.K., Sharpe, P.C., Chambers, C.R., Whatley, S.D., Roberts, A.G., and Elder, G.H. 2004. Hepatoerythropoietic porphyria: A missense mutation in the UROD gene is associated with mild disease and an unusual porphyrin excretion pattern. Br. J. Dermatol. 151:920‐923.
  Badenas, C., To‐Figueras, J., Phillips, J.D., Warby, C.A., Munoz, C., and Herrero, C. 2009. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin. Genet. 75:346‐353.
  Badminton, M.N. and Elder, G.H. 2002. Management of acute and cutaneous porphyrias. Int. J. Clin. Pract. 56:272‐278.
  Badminton, M.N. and Elder, G.H. 2005. Molecular mechanisms of dominant expression in porphyria. J. Inherit. Metab. Dis. 28:277‐286.
  Badminton, M.N., Wheatley, S.D., Deacon, A.C., and Elder, G.H. 2012. The porphyrias and other disorders of porphyrin metabolism. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 5th ed. (C.A. Burtis, E.R. Ashwoo, and D.E. Bruns, eds.) pp. 1031‐1055. Elsevier Saunders, St. Louis, Missouri.
  Badminton, M.N., Elder, G.H., and Whatley, S.D. 2014. Clinical and molecular epidemiology of the porphyrias. In Handbook of Porphyrin Science with Applications in Chemistry, Physics, Materials Science, Engineering, Biology, and Medicine, Vol. 29: Porphyrias and Sideroblastic Anemias (G.C. Ferreira, K.M. Kadish, K.M. Smith, and R. Guilard, eds.) pp. 119‐150. World Scientific Publishing, Hackensack, N.J.
  Balwani, M. and Desnick, R.J. 2012. The porphyrias: Advances in diagnosis and treatment. Blood 120:4496‐4504.
  Barbaro, M., Kotajärvi, M., Harper, P., and Floderus, Y. 2012. Identification of an AluY‐mediated deletion of exon 5 in the CPOX gene by MLPA analysis in patients with hereditary coproporphyria. Clin. Genet. 81:249‐256.
  Berenguer, J., Blasco, J., Cardenal, C., Pujol, T., Cruces Prado, M.J., Herrero, C., Mascaró, J.M., de la Torre, C., and Mercader, J.M. 1997. Hepatoerythropoietic porphyria: Neuroimaging findings. Am. J. Neuroradiol. 18:1557‐1560.
  Bergdahl, I.A., Grubb, A., Schütz, A., Schutz, A., Desnick, R.J., Wetmur, J.G., Sassa, S., and Skerfving, S. 1997. Lead binding to δ‐aminolevulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol. Toxicol. 81:153‐158.
  Berry, A.A., Desnick, R.J., Astrin, K.H., Shabeer, J., Lucky, A.W., and Lim, H.W. 2005. Two brothers with mild congenital erythropoietic porphyria due to a novel genotype. Arch. Dermatol. 141:1575‐1579.
  Bird, T.D., Hamernyik, P., Nutter, J.Y., and Labbe, R.F. 1979. Inherited deficiency of δ‐aminolevulinic acid dehydratase. Am. J. Hum. Genet. 31:662‐668.
  Bissell, D.M., Wang, B., Cimino, T., and Lai, J. 2012. Hereditary coproporphyria. In GeneReviews (Internet) (R.A. Pagon, M.P. Adam, and H.H. Ardinger, et al., eds.). University of Washington, Seattle, Washington. http://www.ncbi.nlm.nih.gov/books/NBK114807/.
  Blake, D., McManus, J., Cronin, V., and Ratnaike, S. 1992. Fecal coproporphyrin isomers in hereditary coproporphyria. Clin. Chem. 38:96‐100.
  Blauvelt, A. 1996. Hepatitis C virus and human immunodeficiency virus infection can alter porphyrin metabolism and lead to porphyria cutanea tarda. Arch. Dermatol. 132:1503‐1504.
  Bleasel, N.R. and Varigos, G.A. 2000. Porphyria cutanea tarda. Aust. J. Dermatol. 41:197‐208.
  Bleiberg, J., Wallen, M., Brodkin, R., and Applebaum, I.L. 1964. Industrially acquired porphyria. Arch. Dermatol. 80:793‐797.
  Bloomer, J.R. and Bonkovsky, H.L. 1989. The pophyrias. Dis. Mon. 35:5‐54.
  Bloomer, J.R., Hill, H.D., Kools, A.M., and Straka, J.G. 1991. Heme synthesis in protoporphyria. Curr. Probl. Dermatol. 20:135‐147.
  Bloomer, J., Wang, Y., Singhal, A., and Risheg, H. 2005. Molecular studies of liver disease in erythropoietic protoporphyria. J. Clin. Gastroenterol. 39:S167‐S175.
  Boisseau, A.M., Couzigou, P., Forestier, J.F., Legrain, V., Aubertin, J., Doutre, M.S., Maleville, J., Geniaux, M., and Beylot, C. 1991. Porphyria cutanea tarda associated with human immunodeficiency virus infection. A study of four cases and review of the literature. Dermatologica 182:155‐159.
  Bonkovsky, H.L. 1982. Porphyrin and heme metabolism and the porphyries. In Hepatology: A Textbook of Liver Disease (D. Zakim and T. Boyer, eds.) pp. 351‐393. Saunders, Philadelphia, Penn.
  Bonkovsky, H.L. 1989. Mechanism of iron potentiation of hepatic uroporphyria: Studies in cultured chick embryo liver cells. Hepatology 10:354‐364.
  Bonkowsky, H.L., Bloomer, J.R., Ebert, P.S., and Mahoney, M.J. 1975. Heme synthetase deficiency in human protoporphyria. Demonstration of the defect in liver and cultured skin fibroblasts. J. Clin. Invest. 56:1139‐1148.
  Bonkovsky, H.L., Healey, J.F., Lincoln, B., Bacon, B.R., Bishop, D.F., and Elder, G.H. 1987. Hepatic heme synthesis in a new model of experimental hemochromatosis: Studies in rats fed finely divided elemental iron. Hepatology 7:1195‐1203.
  Bonkovsky, H.L., Healey, J.F., and Pohl, J. 1990. Purification and characterization of heme oxygenase from chick liver: Comparison of the avian and mammalian enzymes. Eur. J. Biochem. 189:155‐166.
  Bonkovsky, H.L., Poh‐Fitzpatrick, M., Pimstone, N., Obando, J., Di Bisceglie, A., Tattrie, C., Tortorelli, K., LeClair, P., Mercurio, M.G., and Lambrecht, R.W. 1998. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 27:1661‐1669.
  Bovenschen, H.J. and Vissers, W.H.P.M. 2009. Primary hemochromatosis presented by porphyria cutanea tarda: A case report. Cases J. 2:7246.
  Brenner, D.A. and Bloomer, J.R. 1980. The enzymatic defect in variegate porphyria. Studies with human cultured skin fibroblasts. N. Engl. J. Med. 302:765‐769.
  Brodie, M.J., Thompson, G.G., Moore, M.R., Beattie, A.D., and Goldberg, A. 1977. Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood. Q. J. Med. 46:229‐241.
  Bunn, H.F. 2011. UROS and ALAS‐2: Erstwhile partners in crime. Blood 118:1435‐1437.
  Bygum, A., Christiansen, L., Peterson, N.E., Horder, M., Thomsen, K., and Brandrup, F. 2003. Familial and sporadic porphyria cutanea tarda: Clinical, biochemical and genetic features with emphasis on iron status. Acta Derm. Venereol. 83:115‐120.
  Bylesjo, I., Wikberg, A., and Andersson, C. 2009. Clinical aspects of acute intermittent porphyria in northern Sweden: A population‐based study. Scand. J. Clin. Lab. Invest. 69:612‐618.
  Cam, C. and Nigogosyan, G. 1963. Acquired toxic porphyria cutanea tarda due to hexachlorobenzene. J. Am. Med. Assoc. 183:88‐91.
  Campbell, A.E., Wilkinson‐White, L., Mackay, J.P., Mathews, J.M., and Blobel, G.A. 2013. Analysis of disease‐causing GATA1 mutations in murine gene complementation systems. Blood 121:5218‐5227.
  Cantatore‐Francis, J.L., Cohel, J., Balwani, M., Khan, P., Lazarus, H.M., Desnick, R.J., and Schaffer, J.V. 2010. Hepatoerythropoietic porphyria misdiagnosed as child abuse: Cutaneous, arthritic and hematologic manifestations in siblings with a novel UROD mutation. Arch. Dermatol. 146:529‐533.
  Chemmanur, A.T. and Bonkovsky, H.L. 2004. Hepatic porphyrias: Diagnosis and management. Clin. Liver Dis. 8:807‐838.
  Chiaverini, C., Halimi, G., Ouzan, D., Halfon, P., Ortonne, J.P., and Lacour, J.P. 2003. Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: A study from southern France. Dermatology 206:212‐216.
  Chuang, T.Y., Brashear, R., and Lewis, C. 1999. Porphyria cutanea tarda and hepatitis C virus: A case‐control study and meta‐analysis of the literature. J. Am. Acad. Dermatol. 41:31‐36.
  Cox, T.M. 1997. Erythropoietic protoporphyria. J. Inherit. Metab. Dis. 20:258‐269.
  Cox, T. 2003. Protoporphyria. In The Porphyrin Handbook (K.M. Kadish, K.M. Smith, and R. Guilard, eds.) pp. 121‐150. Academic Press, Amsterdam.
  Cribier, B., Rey, D., Uhl, G., Le Coz, C., Hirth, C., Libbrecht, E., Vetter, D., Lang, J.M., Stoll‐Keller, F., and Grosshans, E. 1996. Abnormal urinary coproporphyrin levels in patients infected by hepatitis C virus with or without human immunodeficiency virus. A study of 177 patients. Arch. Dermatol. 132:1448‐1452.
  Cribier, B., Chiaverini, C., Dali‐Youcef, N., Schmitt, M., Grima, M., Hirth, C., Lacour, J.P., and Chosidow, O. 2009. Porphyria cutanea tarda, hepatitis C, uroporphyrinogen decarboxylase and mutations of HFE gene. A case‐control study. Dermatology 218:15‐21.
  Cripps, D.J., Peters, H.A., Gocmen, A., and Dogramici, I. 1984. Porphyria turcica due to hexachlorobenzene: A 20‐30 year follow‐up study on 204 patients. Br. J. Dermatol. 111:413‐422.
  Dabrowska, E., Jablonska‐Kaszewska, I., and Falkiewicz, B. 1998. High prevalence of hepatitis C virus infection in patients with porphyria cutanea tarda in Poland. Clin. Exp. Dermatol. 23:95‐96.
  D'Alessandro Gandolfo, L., Griso, D., Macri, A., Biolcati, G., and Topi, G.C. 1989. Familial porphyria cutanea tarda with normal erythrocytic urodecarboxylase: An exception to the rule? Dermatologica 178:206‐208.
  Day, R.S. and Strauss, P.C. 1982. Severe cutaneous porphyria in a 12‐year‐old boy: Hepatoerythropoietic or symptomatic porphyria? Arch. Dermatol. 118:663‐667.
  De Matteis, F. 1998. Porphyria cutanea tarda of the toxic and sporadic varieties. Clin. Dermatol. 16:265‐275.
  Desnick, R.J. and Astrin, K.H. 2002. Congenital erythropoietic porphyria: Advances in pathogenesis and treatment. Br. J. Haematol. 117:779‐795.
  Desnick, R.J., Glass, I.A., Xu, W., Solis, C., and Astrin, K.H. 1998. Molecular genetics of congenital erythropoietic porphyria. Semin. Liver Dis. 18:77‐84.
  Desnick, R.J., Balwani, M., and Anderson, K.E. 2013. Inherited porphyrias. In Emory and Rimoin's Essential Medical Genetics (D.L. Rimoin, R.E. Pyeritz, and B. Korf, eds.). Academic Press, Kidlington, Oxford.
  Deybach, J.C., Grandchamp, B., Grelier, M., Nordmann, Y., Boué, J., Boué, A., and de Berrianger, P. 1980. Prenatal exclusion of congenital erythropoietic porphyria (Gunther's disease) in a fetus at risk. Hum. Genet. 53:217‐221.
  Deybach, J.C., de Verneuil, H., Phung, N., Nordmann, Y., Puissant, A., and Boffety, B. 1981. Congenital erythropoietic porphyria (Gunther's disease): Enzymatic studies on two cases of late onset. J. Lab. Clin. Med. 97:551‐558.
  Deybach, J.C., Badminton, M., Puy, H., Sandberg, S., Frank, J., Harper, P., Martasek, P., Minder, E., Parker, S., Thunell, S., and Elder, G. 2006. European porphyria initiative (EPI): A platform to develop a common approach to the management of porphyrias and to promote research in the field. Physiol. Res. 55:S67‐S73.
  Di Pierro, E., Besana, V., Moriondo, V., Brancaleoni, V., Tavazzi, D., Casalgrandi, G., Ventura, P., Rocchi, E., and Cappellini, M.D. 2006. A large deletion on chromosome 11 in acute intermittent porphyria. Blood Cells Mol. Dis. 37:50‐54.
  Doss, M. and Schmidt, A. 1972. Zwei suchteste fur porphyrien. Z. Klin. Chem. Klin. Biochem. 10:230‐231.
  Doss, M., Laubenthal, F., and Stoeppler, M. 1984. Lead poisoning in inherited δ‐aminolevulinic acid dehydratase deficiency. Int. Arch. Occup. Environ. Health 54:55‐63.
  Doss, M.O., Frank, M., and Braun‐Falco, O. 1991. Porphyria cutanea tarda: Erythrocyte uroporphyrinogen decarboxylase activity in 471 consecutive patients. Curr. Probl. Dermatol. 20:97‐105.
  Doss, M.O., Stauch, T., Gross, U., Renz, M., Akagi, R., Doss‐Frank, M., Seelig, H.P., and Sassa S. 2004. The third case of Doss porphyria (δ‐amino‐levulinic acid dehydratase deficiency) in Germany. J. Inherit. Metab. Dis. 27:529‐536.
  Dowman, J.K., Gunson, B.K., Bramhall, S., Badminton, M.N., and Newsome, P.N. 2011. Liver transplantation from donors with acute intermittent porphyria. Ann. Intern. Med. 154:571‐572.
  Ducamp, S., Kannengiesser, C., Touati, M., Garçon, L., Guerci‐Bresler, A., Guichard, J.F., Vermylen, C., Dochir, J., Poirel, H.A., Fouyssac, F., Mansuy, L., Leroux, G., Tertian, G., Girot, R., Heimpel, H., Matthes, T., Talbi, N., Deybach, J.C., Beaumont, C., Puy, H., and Grandchamp, B. 2011. Sideroblastic anemia: Molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum. Mutat. 32:590‐597.
  Ducamp, S., Schneider‐Yin, X., de Rooij, F., Clayton, J., Fratz, E.J., Rudd, A., Ostapowicz, G., Varigos, G., Lefebvre, T., Deybach, J.C., Gouya, L., Wilson, P., Ferreira, G.C., Minder, E.I., and Puy, H. 2013. Molecular and functional analysis of the C‐terminal region of human erythroid‐specific 5‐aminolevulinic synthase associated with X‐linked dominant protoporphyria (XLDPP). Hum. Mol. Genet. 22:1280‐1288.
  Eales, L., Day, R.S., and Blekkenhorst, G.H. 1980. The clinical and biochemical features of variegate porphyria: An analysis of 300 cases studied at Groote Schuur Hospital, Cape Town. Int. J. Biochem. 12:837‐853.
  Egger, N.G., Goeger, D.E., Payne, D.A, Miskovsy, E.P., Weinman, S.A., and Anderson, K.E. 2002. Porphyria cutanea tarda: Multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Digest. Dis. Sci. 47:419‐426.
  Elder, G.H. 1990. Porphyria cutanea tarda: A multifactorial disease. Recent Adv. Dermatol. 8:55‐69.
  Elder, G.H. 1997. Hepatic porphyrias in children. J. Inherit. Metab. Dis. 20:237‐246.
  Elder, G.H. 1998. Porphyria cutanea tarda. Semin. Liver Dis. 18:67‐75.
  Elder, G.H. 1999. The cutaneous porphyrias. In Photodermatology (J.L.M. Hawk, ed.) pp. 171‐197. Chapman & Hall, London.
  Elder, G.H. 2003. Porphyria cutanea tarda and related disorders. In The Porphyrin Handbook, Vol. 14 (K. Kadish, K. Smith, and R. Guilard, eds.) p. 67. Elsevier Science, San Diego.
  Elder, G.H. and Roberts, A.G. 1995. Uroporphyrinogen decarboxylase. J. Bioenerg. Biomembr. 27:207‐214.
  Elder, G.H. and Worwood, M. 1998. Mutations in the hemochromatosis gene, porphyria cutanea tarda, and iron overload. Hepatology 27:289‐291.
  Elder, G.H., Smith, S.G., Herrero, C., Lecha, M., Mascaro, J.M., Muniesa, A.M., Czarnecki, D.B., Brenan, J., Poulos, V., and de Salamanca, R.E. 1981. Hepatoerythropoietic porphyria: A new uroporphyrinogen decarboxylase defect or homozygous porphyria cutanea tarda? Lancet 1:916‐919.
  Elder, G.H., Urquhart, A.J., de Salamanca, R.E., Munoz, J.J., and Bonkovsky, H. 1985. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet 2:229‐232.
  Elder, G.H., Roberts, A.G., and de Salamanca, R.E. 1989. Genetics and pathogenesis of human uroporphyrinogen decarboxylase defects. Clin. Biochem. 22:163‐168.
  Elder, G.H., Gouya, L., Whatley, S.D., Puy, H., Badminton, M.N., and Deybach, J.C. 2009. The molecular genetics of erythropoietic protoporphyria. Cell. Mol. Biol. 55:118‐126.
  Elder, G.H., Harper, P., Badminton, M., Sandberg, S., and Deybach, J.C. 2013. The incidence of inherited porphyrias in Europe. J. Inherit. Metab. Dis. 36:849‐857.
  Felsher, B.F., Jones, M.L., and Redeker, A.G. 1973. Iron and hepatic uroporphyrin synthesis. Relation in porphyria cutanea tarda. J. Am. Med. Assoc. 226:663‐665.
  Fernández‐Cuartero, B., Rebollar, J.L., Batlle, A., and Enriquez de Salamanca, R. 1999. Delta‐aminolevulinate dehydratase (ALA‐D) activity in human and experimental diabetes mellitus. Int. J. Biochem. Cell Biol. 31:479‐488.
  Floderus, Y., Shoolingin‐Hordan, P.M., and Harper, P. 2002. Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin. Genet. 62:288‐297.
  Fodinger, M. and Sunder‐Plassmann, G. 1999. Inherited disorders of iron metabolism. Kidney Int. Suppl. 69:S22‐S34.
  Francanzani, A.L., Taioli, E., Sampietro, M., Fatta, E., Bertelli, C., Fiorelli, G., and Fargion, S. 2001. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J. Hepatol. 35:498‐503.
  Frank, J. and Poblete‐Gutierrez, P. 2010. Porphyria cutanea tarda—when skin meets liver. Best Pract. Res. Clin. Gastroenterol. 24:735‐745.
  Frank, J., McGrath, J., Lam, H., Graham, R.M., Hawk, J.L., and Christiano, A.M. 1998. Homozygous variegate porphyria: Identification of both alleles of the protoporphyrinogen oxidase gene in a severely affected proband. J. Invest. Dermatol. 110:452‐455.
  Fritsch, C., Bolsen, K., Ruzicka, T., and Goerz, G. 1997. Congenital erythropoietic porphyria. J. Am. Acad. Dermatol. 36:594‐610.
  Fujita, H., Koizumi, A., Yamamoto, M., Kumai, M., Sadamoto, T., and Ikeda, M. 1984. Inhibition of δ‐aminolevulinate dehydratase in trichloroethylene‐exposed rats, and the effects on heme regulation. Biochim. Biophys. Acta 800:1‐10.
  Fujita, H., Koizumi, A., Hayashi, N., and Ikeda, M. 1986. Reduced synthesis of 5‐aminolevulinate dehydratase in styrene‐treated rats. Biochim. Biophys. Acta 867:89‐96.
  Fujita, H., Sassa, S., Toback, A.C., and Kappas, A. 1987. Immunochemical study of uroporphyrinogen decarboxylase in a patient with mild hepatoerythropoietic porphyria. J. Clin. Invest. 79:1533‐1537.
  Garey, J.R., Harrison, L.M., Franklin, K.F., Metcalf, K.M., Radisky, E.S., and Kushner, J.P. 1990. Uroporphyrinogen decarboxylase: A splice site mutation causes the deletion of exon 6 in multiple families with porphyria cutanea tarda. J. Clin. Invest. 86:1416‐1422.
  Garey, J.R., Franklin, K.F., Brown, D.A., Harrison, L.M., Metcalf, K.M., and Kushner, J.P. 1993. Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda. Gastroenterology 105:165‐169.
  Ged, C., Moreau‐Gaudry, F., Taine, L., Hombrados, I., Calvas, P., Colombies, P., and De Verneuil, H. 1996. Prenatal diagnosis in congenital erythropoietic porphyria by metabolic measurement and DNA mutation analysis. Prenatal Diagn. 16:83‐86.
  Ged, C., Megarbane, H., Chouery, E., Lalanne, M., Megarbane, A., and de Verneuil, H. 2004. Congenital erythropoietic porphyria: Report of a novel mutation with absence of clinical manifestations in a homozygous mutant sibling. J. Invest. Dermatol. 123:589‐591.
  Ged, C., Moreau‐Godry, F., Richard, E., Robert‐Richard, E., and de Verneuil, H. 2009. Congenital erythropoietic porphyria: Mutation update and correlations between genotype and phenotype. Cell. Mol. Biol. 55:53‐60.
  Gisbert, J.P., Garcia‐Buey, L., Pajares, J.M., and Moreno‐Otero, R. 2003. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: Systematic review and meta‐analysis. J. Hepatol. 39:620‐627.
  Goerz, G., Bunselmeyer, S., Bolsen, K., and Schürer, N.Y. 1996. Ferrochelatase activities in patients with erythropoietic protoporphyria and their families. Br. J. Dermatol. 134:880‐885.
  Gomi, H., Hatanaka, K., Miura, T., and Matsuo, I. 1997. Type of impaired porphyrin metabolism caused by hepatitis C virus is not porphyria cutanea tarda but chronic hepatic porphyria. Arch. Dermatol. 133:1170‐1171.
  Gouya, L., Deybach, J.C., Lamoril, J., Da Silva, V., Beaumont, C., Grandchamp, B., and Nordmann, Y. 1996. Modulation of the phenotype in dominant erythropoietic protoporphyria by a low expression of the normal ferrochelatase allele. Am. J. Hum. Genet. 58:292‐299.
  Gouya, L., Puy, H., Robreau, A.M, Bourgeois, M., Lamoril, J., Da Silva, V., Grandchamp, B., and Deybach, J.C. 2002. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat. Genet. 30:27‐28.
  Gouya, L., Martin‐Schmitt, C., Robreau, A‐M., Austerlitz, F., Da Silva, V., Brun, P., Simonin, S., Lyoumi, S., Grandchamp, B., Beaumont, C., Puy, H., and Deybach, J.C. 2006. Contribution of a common single‐nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am. J. Hum. Genet. 78:2‐14.
  Granata, B.X., Parera, V.E., Melito, V.A., Teijo, M.J., Batlle, A.M., and Rossetti, M.V. 2009. The very first description of a patient with hepatoerythropoietic porphyria in Argentina: Biochemical and molecular studies. Cell. Mol. Biol. 55:61‐65.
  Grandchamp, B., Picat, C., Mignotte, V., Wilson, J.H., Te Velde, K., Sandkuyl, L., Roméo, P.H., Goossens, M., and Nordmann, Y. 1989. Tissue‐specific splicing mutation in acute intermittent porphyria. Proc. Natl. Acad. Sci. U.S.A. 86:661‐664.
  Granick, J.L., Sassa, S., and Kappas, A. 1978. Some biochemical and clinical aspects of lead intoxication. In Advances in Clinical Chemistry (O. Bodansky and A.L. Latner, eds.) pp. 287‐339. Academic Press, New York.
  Grossman, M.E. and Poh‐Fitzpatrick, M.B. 1980. Porphyria cutanea tarda. Diagnosis and management. Med. Clin. North Am. 64:807‐827.
  Grossman, M.E., Bickers, D.R., Poh‐Fitzpatrick, M.B., Deleo, V.A., and Harber, L.C. 1979. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients. Am. J. Med. 67:277‐286.
  Gunther, W.W. 1967. The porphyrias and erythropoietic porphyria: An unusual case. Australas J. Dermatol. 9:23‐30.
  Guolo, M., Stella, A.M., Melito, V., Parera, V., and Del C. Batlle, A.M. 1996. Altered 5‐aminolevulinic acid metabolism leading to pseudoporphyria in hemodialysed patients. Int. J. Biochem. Cell Biol. 28:311‐317.
  Hahn, M. and Bonkovsky, H.L. 1998. Disorders of porphyrin metabolism. In Diseases of the Liver and Bile Ducts: A Practical Guide to Diagnosis and Treatment (G. Wu and J. Israel, eds.) pp. 249‐272. Humana Press, Totowa, N.J.
  Held, J.L., Sassa, S., Attalah, K., and Harber, L.C. 1989. Erythrocyte uroporphyrinogen decarboxylase activity in porphyria cutanea tarda: A study of 40 consecutive patients. J. Invest. Dermatol. 93:332‐334.
  Herrick, A.L. and McColl, K.E.L. 2005. Acute intermittent porphyria. Best Pract. Res. Clin. Gastroenterol. 19:235‐249.
  Hift, R.J, Meissner, P.N., Corrigall, A.V., Ziman, M.R., Petersen, L.A., Meissner, D.M., Davidson, B.P., Sutherland, J., Dalley, H.A., and Kirsch, R.E. 1997. Variegate porphyria in South Africa, 1688‐1996—New developments in an old disease. S. Afr. Med. J. 87:722‐731.
  Hift, R.J., Meissner, D., and Meissner, P.N. 2004. A systematic study of the clinical and biochemical expression of variegate porphyria in a large South African family. Brit. J. Dermatol. 151:465‐471.
  Holme, S.A., Anstey, A.V., Finlay, A.Y., Elder, G.H., and Badminton, M.N. 2006. Erythropoietic protoporphyria in the U.K.: Clinical features and effect on quality of life. Br. J. Dermatol. 155:574‐581.
  Horina, J.H. and Wolf, P. 2000. Epoetin for severe anemia in hepatoerythropoietic porphyria. N. Engl. J. Med. 342:1294‐1295.
  Ibrahim, G.W. and Watson, C.J. 1968. Enterohepatic circulation and conversion of protoporphyrin to bile pigment in man. Proc. Soc. Exp. Biol. Med. 127:890‐895.
  Innala, E. and Andersson, C. 2011. Screening for hepatocellular carcinoma in acute intermittent porphyria: A 15‐year follow‐up in northern Sweden. J. Intern. Med. 269:538‐545.
  Jaffe, E.K. and Stith, L. 2007. ALAD porphyria is a conformational disease. Am. J. Hum. Genet. 80:329‐337.
  Jalil, S., Grady, J.J., Lee, C., and Anderson, K.E. 2010. Associations among behavior‐related susceptibility factors in porphyria cutanea tarda. Clin. Gastroenterol. Hepatol. 8:297‐302.
  Jordan, P.M. 1990. The biosynthesis of 5‐aminolevulinic acid and its transformation into coproporphyrinogen in animals and bacteria. In Biosynthesis of Heme and Chlorophylls (H.A. Dailey, ed.) pp. 55‐121. McGraw‐Hill, New York.
  Kappas, A., Sassa, S., and Anderson, K.E. 1983. The porphyrias. In The Metabolic Basis of Inherited Disease, 5th ed. (J.B. Stanbury, J.B. Wyyngaarden, D.S. Fredrickson, J.L. Goldstein, and M.S. Brown, eds.) pp. 1301‐1384. McGraw‐Hill, New York.
  Kappas, A., Sassa, S., Galbraith, R.A., and Nordmann, Y. 1995. The porphyrias. In Metabolic and Molecular Bases of Inherited Disease, Vol. 2, 7th ed. (C.R. Scriver, A.L. Beaudet, W.S. Sly, and D. Valle, eds.) pp. 2103‐2159. McGraw‐Hill, New York.
  Kauppinen, R., Timonen, K., von und zu Fraunberg, M., Laitinen, E., Ahola, H., Tenhunen, R., Taketani, S., and Mustajoki, P. 2001. Homozygous variegate porphyria: 20 y follow‐up and charaterization of molecular defect. J. Invest. Dermatol. 116:610‐613.
  Kirsch, R.E., Meissner, P.N., and Hift, R.J. 1998. Variegate porphyria. Semin. Liver Dis. 18:33‐41.
  Koszo, F., Elder, G.H., Roberts, A., and Simon, N. 1990. Uroporphyrinogen decarboxylase deficiency in hepatoerythropoietic porphyria: Further evidence of genetic heterogeneity. Br. J. Dermatol. 122:365‐370.
  Kühnel, A., Gross, U., and Doss, M.O. 2000. Hereditary coproporphyria in Germany: Clinical‐biochemical studies in 53 patients. Clin. Biochem. 33:465‐473.
  Kuo, H.C., Huang, C.C., Chu, C.C., Lee, M.J., Chuang, W.L., Wu, C.L., Wu, T., Ning, H.C., and Liu, C.Y. 2011. Neurological complications of acute intermittent porphyria. Eur. Neurol. 66:247‐252.
  Kushner, J.P., Barbuto, A.J., and Lee, G.R. 1976. An inherited enzymatic defect in porphyria cutanea tarda: Decreased uroporphyrinogen decarboxylase activity. J. Clin. Invest. 58:1089‐1097.
  Lamoril, J., Boulechfar, S., de Verneuil, H., Grandchamp, B., Nordmann, Y., and Deybach, J.C. 1991. Human erythropoietic protoporphyria: Two point mutations in the ferrochelatase gene. Biochem. Biophys. Res. Commun. 181:594‐599.
  Lamoril, J., Andant, C., Bogard, C., Puy, H., Gouya, L., Pawlotsky, J.M., Da Silva, V., Soulé, J.C., Deybach, J.C., and Nordmann, Y. 1998. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology 27:848‐852.
  Langendonk, J.G., Balwani, M., Anderson, K.E., Bonkovsky, H.L., Anstey, A.V., Bissell, D.M., Bloomer, J.R., Edwards, C., Neumann, N.J., Parker, C., Phillips, J., Lim, H.W., Hamzavi, I., Deybach, J.‐C., Kauppinen, R., Rhodes, L.E., Frank, J., Murphy, G.M., Karstens, F.P.J., Sijbrands, E.J.G., de Rooij, F.W.M., Lebwohl, M., Naik, H., Goding, C.R., Wilson, J.H.P., and Desnick, R.J. 2015. Afamelanotide for erythropoietic protoporphyria. N. Engl. J. Med. In press.
  Lazaro, P., de Slamanca, R.E., Elder, G.H., Villaseca, M.L., Chinarro, S., and Jaqueti, G. 1984. Is hepatoerythropoietic porphyria a homozygous form of porphyria cutanea tarda? Inheritance of uroporphyrinogen decarboxylase deficiency in a Spanish family. Br. J. Dermatol. 110:613‐617.
  Lee, J.S. and Anvret, M. 1991. Identification of the most common mutation within the porphobilinogen deaminase gene in Swedish patients with acute intermittent porphyria. Proc. Natl. Acad. Sci. U.S.A. 8:10912‐10915.
  Lee, D.S., Flachsová, E., Bodnárová, M., Demeler, B., Martásek, P., and Raman, C.S. 2005. Structural basis of hereditary coproporphyria. Proc. Natl. Acad. Sci. U.S.A. 102:14232‐14237.
  Lim, H.W. 1989. Pathophysiology of cutaneous lesions in porphyrias. Semin. Hematol. 26:114‐119.
  Lim, H.W. and Poh‐Fitzpatrick, M.B. 1984. Hepatoerythropoietic porphyria: A variant of childhood‐onset porphyria cutanea tarda. Porphyrin profiles and enzymatic studies of two cases in a family. J. Am. Acad. Dermatol. 11:1103‐1111.
  Lindblad, B., Lindstedt, S., and Steen, G. 1977. On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. U.S.A. 74:4641‐4645.
  Lundvall, O. 1971. The effect of replenishment of iron stores after phlebotomy therapy in porphyria cutanea tarda. Acta Med. Scand. 189:51‐63.
  Macalpine, I. and Hunter, R. 1966. The “insanity” of King George 3rd: A classic case of porphyria. Br. Med. J. 1:65‐71.
  Magnus, I.A., Jarrett, A., Prankerd, T.A.J., and Rimington, C. 1961. Erythropoietic protoporphyria: A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet 2:448‐451.
  Mansourati, F.F., Stone, V.E., and Mayer, K.H. 1999. Porphyria cutanea tarda and HIV/AIDS. A review of pathogenesis, clinical manifestations and management. Int. J. STD AIDS 10:51‐56.
  Maruno, M., Furuyama, K., Akagi, R., Horie, Y., Meguro, K., Garbaczewski, L., Chiorazzi, N., Doss, M.O., Hassoun, A., Mercelis, R., Verstraeten, L., Harper, P., Floderus, Y., Thunell, S., and Sassa S. 2001. Highly heterogeneous nature of δ‐aminolevulinate dehydratase (ALAD) deficiencies in ALAD porphyria. Blood 97:2972‐2978.
  McAlister, F., McClean, K., Hamilton, P.G., and Houston, S. 1995. Human immunodeficiency virus infection and porphyria cutanea tarda: Coexistence of risk factors or causative association? Clin. Infect. Dis. 20:348‐351.
  McColl, K.E., Moore, M.R., Thompson, G.G., and Goldberg, A. 1981. Abnormal haem biosynthesis in chronic alcoholics. Eur. J. Clin. Invest. 11:461‐468.
  McGuire, B.M., Bonkovsky, H.L., Carithers, R.L. Jr., Chung, R.T., Goldstein, L.I., Lake, J.R., Lok, A.S., Potter, C.J., Rand, E., Voigt, M.D., Davis, P.R., and Bloomer, J.R. 2005. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl. 11:1590‐1596.
  McManus, J.F., Begley, C.G., Sassa, S., and Ratnaike, S. 1996. Five new mutations in the uroporphyrinogen decarboxylase gene identified in families with cutaneous porphyria. Blood 88:3589‐3600.
  Meguro, K., Fujita, H., Ishida, N., Akagi, R., Kurihara, T., Galbraith, R.A., Kappas, A., Zabriskie, J.B., Toback, A.C., Harber, L.C., and Sassa, S. 1994. Molecular defects of uroporphyrinogen decarboxylase in a patient with mild hepatoerythropoietic porphyria. J. Invest. Dermatol. 102:681‐685.
  Mehrany, K., Drage, L.A., Brandhagen, D.J., and Pittelkow, M.R. 2004. Association of porphyria cutanea tarda with hereditary hemochromatosis. J. Am. Acad. Dermatol. 51:205‐211.
  Meissner, P.N., Dailey, T.A., Hift, R.J., Ziman, M., Corrigall, A.V., Roberts, A.G., Meissner, D.M., Kirsch, R.E., and Dailey, H.A. 1996. A 59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat. Genet. 13:95‐97.
  Meissner, P., Hift, R.J., and Corrigall, A. 2003. Variegate porphyria. In Phorphyrin Handbook, Part II (K.M. Kadish, K. Smith, and R. Guilard, eds.) p. 93. Academic Press, San Diego.
  Meissner, P.N, Corrigall, A.V., and Hift, R.J. 2012. Fifty years of porphyria at the University of Cape Town. S. Afr. Med. J. 102:422‐426.
  Mendez, M., Sorkin, L., Rossetti, M.V., Astrin, K.H., del C Batlle, A.M., Parera, V.E., Aizencang, G., and Desnick, R.J. 1998. Familial porphyria cutanea tarda: Characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of hemochromatosis alleles. Am. J. Hum. Genet. 63:1363‐1375.
  Minder, E.I. 2010. Afamelanotide, an agonistic analog of α‐melanocyte‐stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. Exp. Opin. Invest. Drugs 19:1591‐1602.
  Moran, M.J., Fontanellas, A., Brudieux, E., Hombrados, I., de Ledinghen, V., Couzigou, P., de Verneuil, H., and De Salamanca, R.E. 1998. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: The influence of virus C infection. Hepatology 27:584‐589.
  Moran‐Jimenez, M.J., Ged, C., Romana, M., Enriquez de Salamanca, R., Taieb, A., Topi, G., Alessandro, L.D., and de Verneuil, H. 1996. Uroporphyrinogen decarboxylase: Complete human gene sequence and molecular study of three families with hepatoerythropoietic porphyria. Am. J. Hum. Genet. 58:712‐721.
  Mukerji, S.K., Pimstone, N.R., and Burns M. 1984. Dual mechanism of inhibition of rat liver uroporphyrinogen decarboxylase activity by ferrous iron: Its potential role in the genesis of porphyria cutanea tarda. Gastroenterology 87:1248‐1254.
  Murphy, A., Gibson, G., Elder, G.H., Otridge, B.A., and Murphy, G.M. 1995. Adult‐onset congenital erythropoietic porphyria (Gunther's disease) presenting with thrombocytopenia. J. R. Soc. Med. 88:357P‐358P.
  Mustajoki, P. 1980. Variegate porphyria. Twelve years' experience in Finland. Q. J. Med. 49:191‐203.
  Nordmann, Y. and Puy, H. 2002. Human hereditary porphyrias. Clin. Chim. Acta 325:17‐37.
  Nordmann, Y., Puy, H., Da Silva, V., Simonin, S., Robreau, A.M., Bonaiti, C., Phung, L.N., and Deybach, J.C. 1997. Acute intermittent porphyria: Prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J. Intern. Med. 242:213‐217.
  Norris, P.G., Nunn, A.V., Hawk, J.L.M., and Cox, T.M. 1991. Genetic heterogeneity in erythropoietic protoporphyria: A study of the enzyme defect in nine affected families. J. Invest. Dermatol. 95:260‐263.
  O'Connor, W.J., Murphy, G.M., Darby, C., Fogarty, J., Mulcahy, F., O'Moore, R., and Barnes, L. 1996. Porphyrin abnormalities in acquired immunodeficiency syndrome. Arch. Dermatol. 132:1443‐1447.
  Oliver, R.M. 1975. Toxic effects of 2,3,7,8 tetrachlorodibenzo‐1,4‐dioxin in laboratory workers. Br. J. Indust. Med. 32:49‐53.
  O'Reilly, F.M., Darby, C., Fogarty, J., O'Moore, R., Courtney, M.G., O'Connor, J., Kay, E.W., Leader, M., Fielding, J.F., and Murphy, G.M. 1996. Porphyrin metabolism in hepatitis C infection. Photodermatol. Photoimmunol. Photomed. 12:31‐33.
  Parsons, J.L., Sahn, E.E., Holden, K.R., and Pai, G.S. 1994. Neurologic disease in a child with hepatoerythropoietic porphyria. Pediatr. Dermatol. 11:216‐221.
  Pawlotsky, J.M., Dhumeaux, D., and Bagot, M. 1995. Hepatitis C virus in dermatology. A review. Arch. Dermatol. 131:1185‐1193.
  Pazderova‐Vejlupková, J., Nemcova, M., Pícková, J., Jirásek, L., and Lukás, E. 1981. The development and prognosis of chronic intoxication by tetrachlorodibenzo‐p‐dioxin in men. Arch. Environ. Health 36:5‐11.
  Peters, T. 2009. Thomas Wakley, King George III and acute porphyria. J. R. Soc. Med. 102:506.
  Phillips, J.D. and Kushner, J.P. 2005. Fast track to the porphyrias. Nat. Med. 11:1049‐1050.
  Phillips, J.D., Bergonia, H.A., Reilly, C.A., Franklin, M.R., and Kushner, J.P. 2007a. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc. Natl. Acad. Sci. U.S.A. 104:5079‐5084.
  Phillips, J.D., Steensma, D.P., Pulsipher, M.A., Spangrude, G.J., and Kushner, J.P. 2007b. Congenital erythropoietic porphyria due to a mutation in GATA1: The first trans‐acting mutation causative for a human porphyria. Blood 109:2618‐2621.
  Phillips, J.D., Whitby, F.G., Stadtmueller, B.M., Edwards, C.Q., Hill, C.P., and Kushner, J.P. 2007c. Two novel uroporphyrinogen decarboxylase (URO‐D) mutations causing hepatoerythropoietic porphyria (HEP). Transl. Res. 149:85‐91.
  Pischik, E. and Kauppinen, R. 2009. Neurological manifestations of acute intermittent porphyria. Cell Mol. Biol. 55:72‐83.
  Poh‐Fitzpatrick, M.B. 1995. Porphyrias. In Cutaneous Medicine and Surgery: An Integrated Program in Dermatology (K.A. Arndt, P.E. LeBoit, J.K. Robinson, and B.U. Wintroub, eds.) pp. 1753‐1762. W.B. Saunders, Philadelphia.
  Potluri, V.R., Astrin, K.H., Wetmur, J.G., Bishop, D.F., and Desnick, R.J. 1987. Human δ‐aminolevulinate dehydratase: Chromosomal localization to 9q34 by in situ hybridization. Hum. Genet. 6:236‐239.
  Puy, H., Gouya, L., and Deybach, J.C. 2010. Porphyrias. Lancet 375:924‐937.
  Rank, J.M., Pascual‐Leone, A., Payne, W., Glock, M., Freese, D., Sharp, H., and Bloomer, J.R. 1991. Hematin therapy for the neurologic crisis of tyrosinemia. J. Pediatr. 118:136‐139.
  Remenyik, E., Lecha, M., Badenas, C., Kószó, F., Vass, V., Herrero, C., Varga, V., Emri, G., Balogh, A., and Horkay, I. 2008. Childhood‐onset mild cutaneous porphyria with compound heterozygotic mutations in the uroporphyrinogen decarboxylase gene. Clin. Exp. Dermatol. 33:602‐605.
  Roberts, A.G., Elder, G.H., de Salamanca, R.E., Herrero, C., Lecha, M., and Mascaro, J.M. 1995. A mutation (G281E) of the human uroporphyrinogen decarboxylase gene causes both hepatoerythropoietic porphyria and overt familial porphyria cutanea tarda: Biochemical and genetic studies on Spanish patients. J. Invest. Dermatol. 104:500‐502.
  Roberts, A.G., Whatley, S.D., Morgan, R.R., Worwood, M., and Elder, G.H. 1997. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 349:321‐323.
  Rocchi, E., Gibertini, P., Cassanelli, M., Pietrangelo, A., Jensen, J., and Ventura E. 1986. Hepatitis B virus infection in porphyria cutanea tarda. Liver 6:153‐157.
  Romeo, G. and Levin, E.Y. 1969. Uroporphyrinogen 3 cosynthetase in human congenital erythropoietic porphyria. Proc. Natl. Acad. Sci. U.S.A. 63:856‐863.
  Romeo, G., Kaback, M.M., and Levin, E.Y. 1970. Uroporphyrinogen 3 cosynthetase activity in fibroblasts from patients with congenital erythropoietic porphyria. Biochem. Genet. 4:659‐664.
  Roméo, P.H., Raich, N., Dubart, A., Beaupain, D., Pryor, M., Kushner, J., Cohen‐Solal, M., and Goossens, M. 1986. Molecular cloning and nucleotide sequence of a complete human uroporphyrinogen decarboxylase cDNA. J. Biol. Chem. 261:9825‐9831.
  Rosipal, R., Lamoril, J., Puy, H., Da Silva, V., Gouya, L., De Rooij, F.W., Te Velde, K., Nordmann, Y., Martàsek P, and Deybach, J.C. 1999. Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and mutation update. Hum. Mutat. 13:44‐53.
  Sampietro, M., Piperno, A., Lupica, L., Arosio, C., Vergani, A., Corbetta, N., Malosio, I., Mattioli, M., Fracanzani, A.L., Cappellini, M.D., Fiorelli, G., and Fargion, S. 1998. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 27:181‐184.
  Sampietro, M., Fiorelli, G., and Fargion, S. 1999. Iron overload in porphyria cutanea tarda. Haematologica 84:248‐253.
  Samuel, D., Boboc, B., Bernuau, J., Bismuth, H., and Benhamou, J.P. 1988. Liver transplantation for protoporphyria. Evidence for the predominant role of the erythropoietic tissue in protoporphyrin overproduction. Gastroenterology 95:816‐819.
  Santos, M., Clevers, H.C., and Marx, J.J. 1997. Mutations of the hereditary hemochromatosis candidate gene HLA‐H in porphyria cutanea tarda. N. Engl. J. Med. 336:1327‐1328.
  Sarkany, R.P.E. 2001. The management of porphyria cutanea tarda. Clin. Exp. Dermatol. 26:225‐232.
  Sarkany, R.P.E. 2008. Making sense of the porphyrias. Photodermatol. Photoimmunol. Photomed. 24:102‐108.
  Sarkany, R.P.E. and Cox, T.M. 1995. Autosomal recessive erythropoietic protoporphyria: A syndrome of severe photosensitivity and liver failure. Q. J. Med. 88:541‐549.
  Sarkany, R.P.E., Alexander, G.J.M.A., and Cox, T.M. 1994. Recessive inheritance of erythropoietic protoporphyria with liver failure. Lancet 343:1394‐1395.
  Sassa, S. 1982. δ‐Aminolevulinic acid dehydratase assay. Enzyme 28:133‐145.
  Sassa, S. 1998. ALAD porphyria. Semin. Liver Dis. 18:95‐101.
  Sassa, S. 2006. Modern diagnosis and management of the porphyrias. Br. J. Haematol. 135:281‐292.
  Sassa, S. and Kappas, A. 1983. Hereditary tyrosinemia and the heme biosynthetic pathway: Profound inhibition of δ‐aminolevulinic acid dehydratase activity by succinylacetone. J. Clin. Invest. 71:625‐634.
  Sassa, S., Granick, S., and Kappas, A. 1975. Effect of lead and genetic factors on heme biosynthesis in the human red cell. Ann. N.Y. Acad. Sci. 244:419‐440.
  Schmid, R. 1960. Cutaneous porphyria in Turkey. N. Engl. J. Med. 263:397‐398.
  Schmitt, C., Gouya, L., Malonova, E., Lamoril, J., Camadro, J.M., Flamme, M., Rose, C., Lyoumi, S., Da Silva, V., Boileau, C., Grandchamp, B., Beaumont, C., Deybach, J.C., and Puy, H. 2005. Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyria or erythropoietic harderoporphyria. Hum. Mol. Genet. 4:3089‐3098.
  Scinicariello, F., Murray, H.E., Moffett, D.B., Abadin, H.G., Sexton, M.J., and Fowler, B.A. 2007. Lead and δ‐aminolevulinic acid dehydratase polymorphism: Where does it lead? A meta‐analysis. Env. Health Perspect. 115:35‐41.
  Sepkowitz, D.V., Hennessey, P., Torno, R.B., and Lampert, M.A. 1995. Hepatic manifestations of porphyria cutanea tarda in a patient with AIDS. Am. J. Gastroenterol. 90:658‐659.
  Shady, A.A., Colby, B.R., Cunha, L.F., Astrin, K.H., Bishop, D.F., and Desnick, R.J. 2002. Congenital erythropoietic porphyria: Identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene. Br. J. Haematol. 117:980‐998.
  Siersema, P.D., Rademakers, L.H., Cleton, M.I., ten Kate, F.J., de Bruijn, W.C., Marx, J.J., and Wilson, J.H. 1995. The difference in liver pathology between sporadic and familial forms of porphyria cutanea tarda: The role of iron. J. Hepatol. 23:259‐267.
  Singal, A.K. and Anderson, K.E. 2013. Variegate porphyria. In: GeneReviews [Internet] (R.A. Pagon, M.P. Adam, H.H., Ardinger, et al., eds.). University of Washington, Seattle. http://www.ncbi.nlm.nih.gov/books/NBK121283/.
  Singal, A.H. and Phillips, J.D. 2014. Porphyria cutanea tarda. In Handbook of Porphyrin Science with Applications in Chemistry, Physics, Materials Science, Engineering, Biology, and Medicine, Vol. 29: Porphyrias and Sideroblastic Anemias (G.C. Ferreira, K.M. Kadish, K.M. Smith, and R. Guilard, eds.) pp. 219‐261. World Scientific Publishing, Hackensack, N.J.
  Singal, A.K., Kormos‐Hallberg, C., Lee, C., Sadagoparamanujam, V.M., Grady, J.J., Freeman, D.J., and Anderson, K.E. 2012. Low‐dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin. Gastroenterol. Hepatol. 10:1402‐1409.
  Smith, S.G. 1986. Hepatoerythropoietic porphyria. Semin. Dermatol. 5:125‐137.
  Stockvis, B.J. 1989. Weekblad van het Nederlandsh Tijdschrift voor Geneeskunde. Second part, no. 13. About two unusual dyes in the urine of patients. Ned. Tijdschr. Geneeskd. 133:2562‐2570, PMID:2689889.
  Stuart, K.A, Busfield, F., Jazwinska, E.C., Gibson, P., Butterworth, L.A., Cooksley, W.G., Powell, L.W., and Crawford, D.H. 1998. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J. Hepatol. 28:404‐409.
  Sweeney, G.D. 1986. Porphyria cutanea tarda, or the uroporphyrinogen decarboxylase deficiency diseases. Clin. Biochem. 19:3‐15.
  Tanigawa, K., Takamura, N., and Yamashita, S. 1995. Congenital erythropoietic porphyria. Nihon Rinsho 53:1422‐1426.
  Thunell, S. and Harper, P. 2000. Porphyrins, porphyrin metabolism, porphyrias. III. Diagnosis, care and monitoring in porphyria cutanea tarda—suggestions for a handling programme. Scand. J. Clin. Lab. Invest. 60:561‐579.
  Thunell, S., Holmberg L., and Lundgren, J. 1987. Aminolaevulinate dehydratase porphyria in infancy. A clinical and biochemical study. J. Clin. Chem. Clin. Biochem. 25:5‐14.
  Thunell, S., Pomp, E., and Brun, A. 2007. Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. Br. J. Clin. Pharm. 64:668‐679.
  Todd, D.J. 1994. Review: Erythropoietic protoporphyria. Br. J. Dermatol. 131:751‐766.
  To‐Figueras, J., Ducamp, S., Clayton, J., Badenas, C., Delaby, C., Ged, C., Lyoumi, S., Gouya, L., de Verneuil, H., Beaumont, C., Ferreira, G.C., Deybach, J.C., Herrero, C., and Puy, H. 2011. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. Blood 118:1443‐1451.
  Touart, D.M. and Sau, P. 1998. Cutaneous deposition diseases. Part I. J. Am. Acad. Dermatol. 39:149‐171.
  Tschudy, D.P., Valsamis, M., and Magnussen, C.R. 1975. Acute intermittent porphyria: Clinical and sected research aspects. Ann. Intern. Med. 83:851‐864.
  Tsukazaki, N., Watanabe, M., and Irifune, H. 1998. Porphyria cutanea tarda and hepatitis C virus infection. Br. J. Dermatol. 138:1015‐1017.
  Verneuil, H., de Aitkne, G., and Nordmann, Y. 1978. Familial and sporadic porphyria cutanea tarda: Two different diseases. Hum. Genet. 44:45‐51.
  Verneuil, H. de, Beaumont, C., Deybach, J.C., Nordmann, Y., Sfar, Z., and Kastally, R. 1984a. Enzymatic and immunological studies of uroporphyrinogen decarboxylase in familial porphyria cutanea tarda and hepatoerythropoietic porphyria. Am. J. Hum. Genet. 36:613‐622.
  Verneuil, H. de, Grandchamp, B., Foubert, C., Weil, D., N'Guyen, V.C., Gross, M.S., Sassa, S., and Nordmann, Y. 1984b. Assignment of the gene for uroporphyrinogen decarboxylase to human chromosome 1 by somatic cell hybridization and specific enzyme immunoassay. Hum. Genet. 66:202‐205.
  Verneuil, H. de, Grandchamp, B., Beaumont, C., Picat, C., and Nordmann, Y. 1986. Uroporphyrinogen decarboxylase structural mutant (Gly281—Glu) in a case of porphyria. Science 234:732‐734.
  Verstraeten, L., Van Regemorter, N., Pardou, A., de Verneuil, H., Da Silva, V., Rodesch, F., et al. 1993. Biochemical diagnosis of a fatal case of Gunther's disease in a newborn with hydrops foetalis. Eur. J. Clin. Chem. Clin. Biochem. 31:121‐128.
  von und zu Fraunberg, M., Timonen, K., Mustajoki, P., and Kauppinen, R. 2002. Clinical and biochemical characteristics and genotype‐phenotype correlation in Finnish variegate porphyria patients. Eur. J. Hum. Genet. 10:649‐657.
  Waldenstrom, J. 1957. The porphyrias as inborn errors of metabolism. Am. J. Med. 22:758‐773.
  Warner, C.A., Poh‐Fitzpatrick, M.B., Zaider, E.F., Tsai, S.F., and Desnick, R.J. 1992. Congenital erythropoietic porphyria. A mild variant with low uroporphyrin I levels due to a missense mutation (A66V) encoding residual uroporphyrinogen III synthase activity. Arch. Dermatol. 128:1243‐1248.
  Warnich, L., Kotze, M.J., Groenewald, I.M., Groenewald, J.Z., van Brakel, M.G., van Heerden, C.J., de Villiers, J.N.P., van der Ven, W.J.M., Schoenmakers, E.F.P.M., Taketani, S., and Retief, A. 1996. Identification of three mutations and associated haplotypes in the protoporphyrinogen oxidase gene in South African families with variegate porphyria. Hum. Mol. Genet. 5:981‐984.
  Went, L.N. and Klasen, E.C. 1984. Genetic aspects of erythropoietic protoporphyria. Ann. Hum. Genet. 48:105‐117.
  Wetmur, J.G., Bishop, D.F., Ostasiewicz, L., and Desnick, R.J. 1986. Molecular cloning of a cDNA for human δ‐aminolevulinate dehydratase. Gene 43:123‐130.
  Wetmur, J.G., Kaya, A.H., Plewinska, M., and Desnick, R.J. 1991. Molecular characterization of the human δ‐aminolevulinate dehydratase 2 (ALAD2) allele: Implications for molecular screening of individuals for genetic susceptibility to lead poisoning. Am. J. Hum. Genet. 49:757‐763.
  Whatley, S.D. and Badminton, M.N. 2005. Acute intermittent porphyria. In: GeneReviews (Internet) (R.A. Pagon, M.P. Adam, H.H. Ardinger, et al., eds.). University of Washington, Seattle. http://www.ncbi.nlm.nih.gov/books/NBK1193/
  Whatley, S.D. and Badminton, M.N. 2013. Role of genetic testing in the management of patients with inherited porphyria and their families. Ann. Clin. Biochem. 50:204‐216.
  Whatley, S.D., Puy, H., Morgan, R.R., Robreau, A.M., Roberts, A.G., Nordmann, Y., Elder, G.H., and Deyback, J.C. 1999. Variegate porphyria in Western Europe: Identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am. J. Hum. Genet. 65:984‐994.
  Whatley, S.D., Ducamp, S., Gouya, L., Grandchamp, B., Beaumont, C., Badminton, M.N., Elder, G.H., Holme, S.A., Anstey, A.V., Parker, M., Corrigall, A.V., Meissner, P.N., Hift, R.J., Marsden, J.T., Ma, Y., Mieli‐Vergani, G., Deybach, J.C., and Puy H. 2008. C‐terminal deletions in the ALAS2 gene lead to gain of function and cause X‐linked dominant protoporphyria without anemia or iron overload. Am. J. Hum. Genet. 83:408‐414.
  Whatley, S.D., Mason, N.G., Woolf, J.R., Newcombe, R.G., Elder, G.H., and Badminton, M.N. 2009. Diagnostic strategies for autosomal dominant acute porphyrias: Retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin. Chem. 55:1406‐1414.
  Whatley, S.D., Mason, N.G., Holme, S.A., Anstey, A.V., Elder, G.H., and Badminton, M.N. 2010. Molecular epidemiology of erythropoietic protoporphyria in the U.K. Br. J. Dermatol. 162:642‐646.
  Wissel, P.S., Sordillo, P., Anderson, K.E., Sassa, S., Savillo, R.L., and Kappas, A. 1987. Porphyria cutanea tarda associated with the acquired immune deficiency syndrome. Am. J. Hematol. 25:107‐113.
  Xu, W., Warner, C.A., and Desnick, R.J. 1995. Congenital erythropoietic porphyria: Identification and expression of 10 mutations in the uroporphyrinogen III synthase gene. J. Clin. Invest. 95:905‐912.
PDF or HTML at Wiley Online Library